Q2 2022 EPS Estimates for bluebird bio, Inc. Lowered by William Blair (NASDAQ:BLUE)

bluebird bio, Inc. (NASDAQ:BLUEGet Rating) – Equities researchers at William Blair lowered their Q2 2022 EPS estimates for bluebird bio in a report issued on Monday, May 9th. William Blair analyst R. Prasad now anticipates that the biotechnology company will post earnings per share of ($1.27) for the quarter, down from their prior estimate of ($1.23). William Blair also issued estimates for bluebird bio’s Q3 2022 earnings at ($1.05) EPS, Q4 2022 earnings at ($0.98) EPS, FY2022 earnings at ($4.96) EPS, Q1 2023 earnings at ($0.82) EPS, Q2 2023 earnings at ($0.83) EPS, Q3 2023 earnings at ($0.83) EPS, Q4 2023 earnings at ($0.84) EPS and FY2023 earnings at ($3.32) EPS.

A number of other research firms have also weighed in on BLUE. Wedbush dropped their price objective on bluebird bio from $10.00 to $8.00 and set a “neutral” rating for the company in a research note on Tuesday. Morgan Stanley dropped their price objective on bluebird bio from $6.00 to $5.00 and set an “underweight” rating for the company in a research note on Monday, March 7th. SVB Leerink dropped their price objective on bluebird bio from $10.00 to $8.00 and set a “market perform” rating for the company in a research note on Wednesday, April 6th. StockNews.com started coverage on bluebird bio in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Finally, Barclays dropped their price objective on bluebird bio from $4.00 to $3.00 in a research note on Tuesday. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $12.14.

NASDAQ:BLUE opened at $3.57 on Thursday. The stock has a 50-day simple moving average of $4.42 and a two-hundred day simple moving average of $8.06. bluebird bio has a 52-week low of $3.11 and a 52-week high of $35.59. The firm has a market capitalization of $255.09 million, a PE ratio of -0.34 and a beta of 1.63.

bluebird bio (NASDAQ:BLUEGet Rating) last posted its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.10). The firm had revenue of $1.95 million for the quarter, compared to analysts’ expectations of $0.17 million. bluebird bio had a negative net margin of 2,183.15% and a negative return on equity of 111.73%. The firm’s revenue was up 117.6% compared to the same quarter last year. During the same quarter last year, the company posted ($3.07) EPS.

A number of hedge funds have recently modified their holdings of the business. State Street Corp raised its position in bluebird bio by 70.4% during the fourth quarter. State Street Corp now owns 7,617,310 shares of the biotechnology company’s stock valued at $76,097,000 after purchasing an additional 3,147,374 shares during the period. BlackRock Inc. raised its position in bluebird bio by 2.5% during the fourth quarter. BlackRock Inc. now owns 5,912,002 shares of the biotechnology company’s stock valued at $59,058,000 after purchasing an additional 142,293 shares during the period. First Trust Advisors LP raised its holdings in shares of bluebird bio by 126.3% in the fourth quarter. First Trust Advisors LP now owns 5,204,825 shares of the biotechnology company’s stock worth $51,996,000 after buying an additional 2,904,800 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of bluebird bio by 14.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,215,910 shares of the biotechnology company’s stock worth $22,136,000 after buying an additional 283,213 shares during the period. Finally, Credit Suisse AG raised its holdings in shares of bluebird bio by 9.7% in the fourth quarter. Credit Suisse AG now owns 2,199,297 shares of the biotechnology company’s stock worth $21,972,000 after buying an additional 195,005 shares during the period. Institutional investors and hedge funds own 96.38% of the company’s stock.

About bluebird bio (Get Rating)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

Recommended Stories

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.